Zanubrutinib Combined With BR in the First-line Treatment of Waldenström's Macroglobulinemia

NCT06942507 · clinicaltrials.gov ↗

NA

Phase

NOT_YET_RECRUITING

Status

104

Enrollment

OTHER

Sponsor class

Conditions

Waldenström's Macroglobulinemia (WM)

Interventions

DRUG: Zanubrutinib
DRUG: Bendamustine + Rituximab

Sponsor

Peking Union Medical College Hospital